For patients with cancer driven by alterations in genes that are beyond the reach of conventional therapies.

For many oncology targets, selectivity and depth
of engagement are critical feature of the most impactful drugs.

We were founded by Cormorant Asset Management, LP, a leading life sciences focused investment firm.

Learn More

If you are interested to learn more about our work or would like to speak with us about partnership opportunities, please contact us.